Movement Alert|TG Therapeutics Intraday Rise 5.41% in Regular Trading, Revenue Beat and Full-Year Outlook Raised

Market Focus11-10

On November 10, TG Therapeutics rose 5.41% in Regular Trading, with shares trading at $62.78 and turnover reaching $207 million.

The move followed its latest quarterly results, which showed third-quarter revenue of $259.9 million, above the $245.5 million market expectation, alongside an increase in total global revenue guidance to about $1.0 billion from $950 million previously.

Profit was mixed: diluted EPS came in at $0.35, versus $2.43 a year earlier and slightly below some forecasts, but revenue increased from $161.7 million a year ago. The market reaction suggests investors focused more on stronger top-line growth and the higher full-year outlook, indicating continued commercialization momentum for the company’s core multiple sclerosis product portfolio.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment